American Association for Cancer Research
10780432ccr071376-sup-supplementary_tables_s1-s2.pdf (14.41 kB)

Supplementary Tables S1-S2 from Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer Patients

Download (14.41 kB)
journal contribution
posted on 2023-03-31, 15:24 authored by Paula Schaiquevich, John C. Panetta, Lisa C. Iacono, Burgess B. Freeman, Victor M. Santana, Amar Gajjar, Clinton F. Stewart
Supplementary Tables S1-S2 from Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer Patients



Purpose: To characterize the population pharmacokinetics of topotecan lactone in children with cancer and identify covariates related to topotecan disposition.Patients and Methods: The study population consisted of 162 children in seven clinical trials receiving single agent topotecan as a 30-min infusion. A population approach via nonlinear mixed effects modeling was used to conduct the analysis.Results: A two-compartment model was fit to topotecan lactone plasma concentrations (n = 1874), and large pharmacokinetic variability was observed among studies, among individuals, and within individuals. We conducted a covariate analysis using demographics, biochemical data, trial effects, and concomitant drugs. The most significant covariate was body surface area, which explained 54% of the interindividual variability for topotecan systemic clearance. Interoccasion variability was considerable in both clearance and volume (20% and 22%, respectively), but was less than interindividual variability in both variables. Other covariates related to clearance were concomitant phenytoin, calculated glomerular filtration rate, and age (<0.5 years). Including them in the model reduced the interindividual variability for topotecan clearance by an additional 48% relative to the body surface area–normalized model. The full covariate model explained 76% and 50% of interindividual variability in topotecan clearance and volume, respectively.Conclusions: We developed a descriptive and robust population pharmacokinetic model which identified patient covariates that account for topotecan disposition in pediatric patients. Additionally, dosing topotecan based on the covariate model led to a more accurate and precise estimation topotecan systemic exposure compared with a fixed dosing approach, and could be a tool to assist clinicians to individualize topotecan dosing.

Usage metrics

    Clinical Cancer Research





    Ref. manager